亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Precision Medicine and Immunotherapy Have Arrived for Cholangiocarcinoma: An Overview of Recent Approvals and Ongoing Clinical Trials

医学 精密医学 克拉斯 内科学 临床试验 肿瘤科 血液学 癌症 肝内胆管癌 引用 结直肠癌 图书馆学 病理 计算机科学
作者
Thomas Benjamin Karasic,Jennifer Rachel Eads,Lipika Goyal
出处
期刊:JCO precision oncology [Lippincott Williams & Wilkins]
卷期号:7 (7): e2200573-e2200573 被引量:13
标识
DOI:10.1200/po.22.00573
摘要

Article Tools REVIEW ARTICLES Precision Medicine Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/PO.22.00573 JCO Precision Oncology no. 7 (2023) e2200573. Published online April 13, 2023. PMID: 37053534 Precision Medicine and Immunotherapy Have Arrived for Cholangiocarcinoma: An Overview of Recent Approvals and Ongoing Clinical Trials Thomas B. Karasic , MD1xThomas B. KarasicSearch for articles by this author; Jennifer R. Eads , MD1xJennifer R. EadsSearch for articles by this author; and Lipika Goyal , MD, MPhil2xLipika GoyalSearch for articles by this author Show More 1Division of Hematology/Oncology, University of Pennsylvania, Philadelphia, PA2Department of Medicine, Division of Hematology and Oncology, Stanford Cancer Center, Palo Alto, CA https://doi.org/10.1200/PO.22.00573 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologyCONTEXTKey ObjectiveTo summarize recent advances in precision medicine and immunotherapy for patients with cholangiocarcinoma.Knowledge GeneratedTargetable alterations are found in up to 40%-50% of patients with intrahepatic cholangiocarcinoma and up to 15%-20% of patients with extrahepatic cholangiocarcinoma. Effective therapies exist for FGFR2 fusions, IDH1 mutations, BRAF V600E mutations, NTRK and RET fusions, HER2 amplification/overexpression, MSI-high tumors, and TMB-high tumors, and data continue to emerge for other potential targets such as KRAS G12C mutations, MDM2 amplifications, and DNA repair deficiencies.RelevanceThe emerging therapies outlined in this review are likely to reshape the treatment landscape for cholangiocarcinoma in the coming years.SUPPORTL.G. receives funding from the American Cancer Society Clinical Scientist Development Grant 134,013‐CSDG‐19‐163‐01‐T.B.G., the NIH/NCI Gastrointestinal Cancer SPORE P50 CA127003, V Foundation for Cancer Research Translational Grant, and the Cholangiocarcinoma Foundation Andrea Marie Fuquay Research Fellowship.AUTHOR CONTRIBUTIONSConception and design: All authorsCollection and assembly of data: Thomas B. Karasic, Lipika GoyalData analysis and interpretation: All authorsManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Thomas B. KarasicHonoraria: Incyte, Pfizer, Ipsen, AstraZeneca/MedImmune, Taiho OncologyConsulting or Advisory Role: Nucorion, IncyteResearch Funding: Taiho Pharmaceutical (Inst), H3 Biomedicine (Inst), Bristol Myers Squibb (Inst), Lilly (Inst), Tempest Therapeutics (Inst), Xencor (Inst), Genentech (Inst)Jennifer R. EadsEmployment: Bristol Myers Squibb, Janssen OncologyStock and Other Ownership Interests: Bristol Myers Squibb/CelgeneConsulting or Advisory Role: Advanced Accelerator ApplicationsResearch Funding: Xencor (Inst), Tarveda Therapeutics (Inst), MedImmune (Inst), Incyte, Oncolys BioPharma (Inst), Seattle Genetics (Inst), Genentech (Inst), Hutchison MediPharma (Inst), AstraZeneca/MedImmune (Inst)Travel, Accommodations, Expenses: Bristol Myers Squibb, Janssen OncologyLipika GoyalConsulting or Advisory Role: Alentis Therapeutics, QED Therapeutics, AstraZeneca, Taiho Pharmaceutical, Incyte, Sirtex Medical, Genentech, Exelixis, TransThera Biosciences, Merck, Black Diamond Therapeutics, Synthekine, Eisai/H3 Biomedicine, Tyra Biosciences, Kinnate Biopharma, Compass Therapeutics, Blueprint Medicines, SERVIERUncompensated Relationships: Boehringer IngelheimNo other potential conflicts of interest were reported.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
等于完成签到 ,获得积分10
3秒前
泠珞完成签到,获得积分20
3秒前
7秒前
Orange的应助被zhp采纳,获得10
9秒前
12秒前
mickaqi完成签到 ,获得积分10
16秒前
风中的芷珍完成签到,获得积分10
16秒前
正直立果发布了新的文献求助30
22秒前
谦让妙芹完成签到,获得积分10
23秒前
hyman发布了新的文献求助10
24秒前
秀丽的斓完成签到,获得积分10
25秒前
英姑的应助被听话的含羞草采纳,获得10
29秒前
上衫绘梨衣完成签到 ,获得积分10
32秒前
HYZJIA1完成签到 ,获得积分10
41秒前
42秒前
霸气的远望完成签到 ,获得积分10
44秒前
研究完成签到 ,获得积分10
48秒前
泠珞发布了新的文献求助10
50秒前
犹豫静白完成签到,获得积分10
51秒前
Ariel完成签到,获得积分10
52秒前
清新的雨文完成签到,获得积分10
53秒前
qiu完成签到,获得积分10
1分钟前
Alicia完成签到 ,获得积分10
1分钟前
三泥完成签到,获得积分10
1分钟前
香蕉觅云的应助被科研通管家采纳,获得10
1分钟前
CAOHOU的应助被科研通管家采纳,获得10
1分钟前
科研通AI65的应助被科研通管家采纳,获得10
1分钟前
隐形曼青的应助被科研通管家采纳,获得10
1分钟前
FA完成签到 ,获得积分10
1分钟前
科研通AI65的应助被科研通管家采纳,获得10
1分钟前
1分钟前
1分钟前
笙笙的应助被科研通管家采纳,获得10
1分钟前
852的应助被科研通管家采纳,获得10
1分钟前
orixero的应助被科研通管家采纳,获得10
1分钟前
1分钟前
小糖完成签到,获得积分10
1分钟前
笙笙的应助被科研通管家采纳,获得10
1分钟前
cnspower的应助被科研通管家采纳,获得10
1分钟前
科研通AI65的应助被科研通管家采纳,获得10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184980
求助须知:如何正确求助?哪些是违规求助? 9573917
关于积分的说明 21833751
捐赠科研通 7782440
什么是DOI,文献DOI怎么找? 3434429
关于科研通互助平台的介绍 2558672
邀请新用户注册赠送积分活动 2481161